Life Science Compliance Update

« February 22, 2010 | Main | February 24, 2010 »

4 posts from February 23, 2010

February 23, 2010

University of South Florida: Nobel Prize Winner Lectures on Working with the Pharmaceutical Industry


Many medical schools are running away from industry, but one university is embracing the outcomes of working with Industry.  The Dean of the University of South Florida is hosting on March 4th Nobel Laureate Alfred Gilman, MD, PhD in a lecture titled:

USF Deans Lecture

Why is Everyone Picking on the Pharmaceutical Industry

And Yes, I have a Financial Conflict of Interest

A pro and con discussion of the pharmaceutical industry’s current status,

Including consideration of public affairs issues

Cocktail Reception: 5:00pm-7:00pm

Lecture: 7:00pm-8:00pm

Sponsored by USF Health

In addition they are also holding a panel discussion on the important topic of transparency and objectivity:

Tenth USF Symposium on Bioethics Conflicts of Interest

Balancing Entrepreneurship with Objectivity and Transparency

University of South Florida Discussion with Alfred Gilman, MD, PhD

Panel Discussion: 3:00pm-5:00pm

Jointly Sponsored by

USF Division of Research Integrity & Compliance &

USF Bioethics and Medical Humanities


For more information and to register visit


No registration fee for these activities.

Registrations must be received by March 1st

About Lecturer:

Alfred Gilman, MD, PhD

1994 Nobel Laureate in Physiology or Medicine

Alfred G. Gilman, MD, PhD co-founded Regeneron Pharmaceuticals, Inc and is currently the Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas.

He served as Executive Vice President for Academic Affairs and Provost at the University of Texas Southwestern Medical Center in Dallas as well as Dean of Southwestern Medical School. Dr. Gilman is an American biochemist who shared the 1994 Nobel Prize in Physiology or Medicine with Martin Rodbell for their discovery of G-proteins and their role in signal transduction within the cell.

He received a Bachelor of Science degree summa cum laude in Biochemistry from Yale University and his Doctor of Medicine and Doctorate in Pharmacology degrees from Case Western Reserve University in Cleveland, Ohio.

Dr. Gilman has been the recipient of many awards including the American Heart Association Basic Science Research Prize in 1990, American Cancer Society Medal of Honor in 1995, Albert Lasker Basic Medical Research Award in 1989, and The Gairdner Foundation International Award in 1984.


Obama Health Care Plan: Optimistically Short on Details

In anticipation of the health care summit this Thursday and as promised, President Obama “unveiled proposed healthcare legislation that includes provisions designed to improve access to prescription drugs and increase generic drug availability.” The overall total spending for the bill expected to cost $950 billion over 10 years and provide coverage to more than 31 million uninsured Americans.

The bill also includes an increase in the fees the pharmaceutical industry pays starting in 2011. The increase is expected to help close the Medicare "donut-hole" gap for prescription drug coverage, “which leaves seniors paying the full cost of medicines.” In fact, Mr. Obama’s plan this time completely closes the gap, a change from the bill passed in the House in December.

Consequently, his new proposal increases requirements on the pharmaceutical industry over 10 years by “$10 billion above the $23-billion increase proposed under the Senate bill.” These fees however, will not be implemented until 2011. To support these changes, the administration asserted that the increased money will result in expanding health coverage and closing the donut hole, giving the pharmaceutical industry new revenue.

With regards to the drug industry as well, Obama’s proposal gives the Federal Trade Commission the authority to address the practice of "pay for delay" agreements between brand name and generic drug manufacturers. In doing so, the President hopes to increase access to generic drugs.

The particular provision would prohibit “generic drug manufacturers from accepting anything of value from a brand-name manufacturer that contains a provision in which the generic drug manufacturer agrees to limit or forgo research, development, marketing, manufacturing or sales of the generic drug." Such deals could only be reached if the parties "demonstrate by clear and convincing evidence that the pro-competitive benefits of the agreement outweigh the anti-competitive effects of the agreement."

Other features include:

· Taxes on high value insurance plans

· Mandates on Individuals to buy insurance

· Employer mandates with fines of up to $2,000 per employee

· Medicare taxes on investment income (this will go over big with the AARP crowd)

· Regulated insurance premiums

While the plan will be debated Thursday at the bipartisan healthcare summit, many Republicans are angered. House Republican leader John Boehner said Obama was “undermining the Feb. 25 meeting by proposing the same massive government takeover of health care based on a partisan bill the American people have already rejected.”  Ultimately, this attempt for an “opening bid” for the health care summit may end up being the only bid.

The president’s proposal is surprisingly short (25 pages, utilizing short narrative paragraphs) in comparison, the House and Senate bills are each over 2,000 pages long.    One would hope that the president’s bill would be shorter and presented soon after the summit.  The plan is optimistic but short on details.

Links to Proposal and Key Documents

White House Summary of Health Care Reform Proposal

White House Key Documents

Wall Street Journal


Preview | Powered by FeedBlitz


August 2015
Sun Mon Tue Wed Thu Fri Sat
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31